HIV controllers maintain a population of highly efficient Th1 effector cells in contrast to patients treated in the long term

Journal of Virology

Volumn 86, Issue 19, 2012, Pages 10661-10674

  Vingert, Benoît ^a,h   Benati, Daniela ^a   Lambotte, Olivier ^b,c   De Truchis, Pierre ^d   Slama, Laurence ^e   Jeannin, Patricia ^a   Galperin, Moran ^a   Perez Patrigeon, Santiago ^a,i   Boufassa, Faroudy ^b   Kwok, William W ^f   Lemaître, Fabrice ^g   Delfraissy, Jean François ^b,c   Thèze, Jacques ^a   Chakrabarti, Lisa A ^a  

^a INSTITUT PASTEUR   (France)

^b BICÊTRE HOSPITAL   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d RAYMOND POINCARÉ HOSPITAL   (France)

^e HÔPITAL TENON   (France)

^f BENAROYA RESEARCH INSTITUTE   (United States)

^g INSTITUT PASTEUR   (France)

^h HENRI MONDOR HOSPITAL   (France)

ⁱ INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; GAG PROTEIN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 21; INTERLEUKIN 4; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PERFORIN;

ADULT; AGED; ARTICLE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; EFFECTOR CELL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREGULATION; LONG TERM CARE; LYMPHOCYTE SUBPOPULATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; TH1 CELL; TREATMENT RESPONSE; VIRUS LOAD;

EID: 84869050052     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00056-12     Document Type: Article

References (85)

1. Appay V, Iglesias MC. 2011. Antigen sensitivity and T-cell receptor avidity as critical determinants of HIV control. Curr. Opin. HIV AIDS 6:157-162.
2. +) CTLs ex vivo. J. Immunol. 168:5954-5958.
3. Blankson JN. 2010. Effector mechanisms in HIV-1 infected elite controllers: highly active immune responses? Antiviral Res. 85:295-302.
4. Boufassa F, et al. 2011. CD4 dynamics over a 15 year-period among HIV controllers enrolled in the ANRS French observatory. PLoS One. 6:e18726. doi:10.1371/journal.pone.0018726.
5. Brenchley JM, et al. 2008. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood 112:2826-2835.
6. Brenchley JM, et al. 2006. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12:1365-1371
7. Brockman MA, et al. 2009. IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells. Blood. 114:346-356.
8. + T lymphocytes with cellular maturation. J. Exp. Med. 203:2865-2877.
9. Chakrabarti LA, Simon V. 2010. Immune mechanisms of HIV control. Curr. Opin. Immunol. 22:488-496.
10. Charron D. 1997. HLA, vol. 2. Genetic diversity of HLA, functional and medical implications. Proceedings of the 12th International Histocompatibility Workshop and Conference. EDK, Sèvres, Paris.
11. + T cell function. J. Virol. 85:733-741.
12. +T cells, including Th17 and cycling subsets, are intact in the gut mucosa of HIV-1-infected long-term nonprogressors. J. Virol. 85:5880-5888.
13. Davis MM, Altman JD, Newell EW. 2011. Interrogating the repertoire: broadening the scope of peptide-MHC multimer analysis. Nat. Rev. Immunol. 11:551-558.
14. Deeks SG. 2011. HIV infection, inflammation, immunosenescence, and aging. Annu. Rev. Med. 62:141-155.
15. Deeks SG, Walker BD. 2007. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity. 27:406-416.
16. Douek DC, Roederer M, Koup RA. 2009. Emerging concepts in the immunopathogenesis of AIDS. Annu. Rev. Med. 60:471-484.
17. Dragsted UB, et al. 2004. Predictors of immunological failure after initial response to highly active antiretroviral therapy in HIV-1-infected adults: a EuroSIDA study. J. Infect. Dis. 190:148-155.
18. Elsaesser H, Sauer K, Brooks DG. 2009. IL-21 is required to control chronic viral infection. Science. 324:1569-1572.
19. Emu B, et al. 2005. Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J.Virol. 79:14169-14178.
20. + T-cell responses. J. Virol. 84:11020-11029.
21. Gabrysova L, et al. 2009. Negative feedback control of the autoimmune response through antigen-induced differentiation of IL-10-secreting Th1 cells. J. Exp. Med. 206:1755-1767.
22. Ghoreschi K, Laurence A, Yang XP, Hirahara K, O'Shea JJ. 2011. T helper 17 cell heterogeneity and pathogenicity in autoimmune disease. Trends Immunol. 32:395-401.
23. Grabar S, et al. 2009. Prevalence and comparative characteristics of longterm nonprogressors and HIV controller patients in the French Hospital Database on HIV. AIDS. 23:1163-1169.
24. Guihot A, et al. 2010. Immune and virological benefits of 10 years of permanent viral control with antiretroviral therapy. AIDS 24:614-617.
25. Harari A, et al. 2006. Functional signatures of protective antiviral T-cell immunity in human virus infections. Immunol. Rev. 211:236-254.
26. Harari A, Petitpierre S, Vallelian F, Pantaleo G. 2004. Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood 103:966-972.
27. + T-cell cytotoxic potential in HIV elite controllers is associated with T-bet expression. Blood 117:3799-3808.
28. +T-cell response associated with immunologic control. Curr. Opin. HIV AIDS. 6:169-173.
29. Hersperger AR, et al. 2010. Perforin expression directly ex vivo by HIVspecific CD8 T-cells is a correlate of HIV elite control. PLoS Pathog. 6:e1000917. doi:10.1371/journal.ppat.1000917.
30. + T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J. Infect. Dis. 197:126-133.
31. + T cells may contribute to viral persistence in HIV controllers. Clin. Infect. Dis. 52:681-687.
32. Hunt PW, et al. 2011. A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. PLoS One 6:e15924. doi:10.1371/journal.pone.0015924.
33. Iannello A, et al. 2010. Dynamics and consequences of IL-21 production in HIV-infected individuals: a longitudinal and cross-sectional study. J. Immunol. 184:114-126.
34. + T cells and viremia: who's in control? Trends Immunol. 27:119-124.
35. + T cell responses without high-frequency fixation of mutations. J. Virol. 83: 8722-8732.
36. Kannanganat S, et al. 2007. Human immunodeficiency virus type 1 controllers but not noncontrollers maintain CD4 T cells coexpressing three cytokines. J. Virol. 81:12071-12076.
37. +T cell function by multiple costimulatory receptors during chronic HIV infection. J. Immunol. 185:3007-3018.
38. Kaufmann DE, et al. 2004. Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides.J. Virol. 78:4463-4477.
39. + T cells correlates with disease progression and defines a reversible immune dysfunction. Nat. Immunol. 8:1246-1254.
40. Kaufmann DE, et al. 2004. Limited durability of viral control following treated acute HIV infection. PLoS Med. 1:e36. doi:10.1371/ journal.pmed.0010036.
41. Kaufmann GR, et al. 2005. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to =500 cells/microL in HIV type 1-in-fected individuals receiving potent antiretroviral therapy. Clin. Infect. Dis.41:361-372.
42. Klatt NR, Brenchley JM. 2010. Th17 cell dynamics in HIV infection. Curr. Opin. HIV AIDS 5:135-140.
43. Kwok WW. 2003. Challenges in staining T cells using HLA class II tetramers. Clin. Immunol. 106:23-28.
44. +) T cells using MHC class II multimer bead sorting and immunoscope analysis. Eur. J. Immunol. 34:2941-2949.
45. Lichterfeld M, Pantaleo G, Altfeld M. 2005. Loss of HIV-1-specific T cell proliferation in chronic HIV-1 infection: cause or consequence of viral replication? AIDS 19:1225-1227.
46. + T-cell restoration in gut-associated lymphoid tissue of HIV-infected patients is associated with enhanced Th17 cells and polyfunctional HIV-specific T-cell responses. Mucosal Immunol.1:475-488.
47. Mallone R, Nepom GT. 2004. MHC class II tetramers and the pursuit of antigen-specific T cells: define, deviate, delete. Clin. Immunol. 110:232-242.
48. +T cells is required for HIV-infected cell elimination associated with immune control. Immunity 29:1009-1021.
49. Ndhlovu LC, et al. 2008. Suppression of HIV-1 plasma viral load below detection preserves IL-17 producing T cells in HIV-1 infection. AIDS. 22: 990-992.
50. +T-cell response in different phases of HIV infection. AIDS 24:947-957.
51. +) T cells proliferating in response to influenza A antigen. J. Clin. Invest. 104:R63-R67.
52. +elite controllers have low HIV-specific T-cell activation yet maintain strong, polyfunctional T-cell responses. AIDS. 24: 1095-1105.
53. Palmer S, et al. 2008. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl. Acad. Sci. U. S. A. 105:3879-3884.
54. Pereyra F, et al. 2009. Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters. J. Infect. Dis. 200:984-990.
55. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat. Med. 5:518-525.
56. Porichis F, Kaufmann DE. 2011. HIV-specific CD4 T cells and immune control of viral replication. Curr. Opin. HIV AIDS. 6:174-180.
57. Porichis F, et al. 2011. Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood. 118:965-974.
58. +T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J. Virol. 81:13904-13915.
59. +Th17 cells and gradual decline in regulatory T cells. AIDS. 24:491-502.
60. Ranasinghe S, et al. 2012. HIV-specific CD4 T cell responses to different viral proteins have discordant associations with viral load and clinical outcome. J. Virol. 86:277-283.
61. Roederer M, Nozzi JL, Nason MC. 2011. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 79:167-174.
62. + T cell responses associated with control of viremia. Science. 278:1447-1450.
63. + T cells recognize and inhibit SIV replication in infected macrophages early after infection. Proc. Natl. Acad. Sci. U. S. A. 106:9791-9796.
64. Saez-Cirion A, et al. 2007. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar CTL activation phenotype. Proc. Natl. Acad. Sci. U. S. A. 104:6776-6781.
65. + T cell activation during HIV infection. Nat. Med. 16:452-459.
66. Sajadi MM, Shakeri N, Talwani R, Redfield RR. 2010. Hepatitis C infection in HIV-1 natural viral suppressors. AIDS 24:1689-1695.
67. Salgado M, et al. 2011. Long-term non-progressors display a greater number of Th17 cells than HIV-infected typical progressors. Clin. Immunol. 139:110-114.
68. + T lymphocyte turnover and activation increase upon viral rebound. J. Clin. Invest. 115:443-450.
69. Seth N, Kaufmann D, Lahey T, Rosenberg ES, Wucherpfennig KW. 2005. Expansion and contraction of HIV-specific CD4 T cells with short bursts of viremia, but physical loss of the majority of these cells with sustained viral replication. J. Immunol. 175:6948-6958.
70. Soghoian DZ, et al. 2012. HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci. Transl. Med. 4:123ra125.
71. + T cells are a consequence of antigen load.J. Virol. 81:2713-2725.
72. Torheim EA, et al. 2009. Interleukin-10-secreting T cells define a suppressive subset within the HIV-1-specific T-cell population. Eur. J. Immunol. 39:1280-1287.
73. +) T cells during HIV infection. Nat. Med. 14:266-274.
74. + T cells respond to minimal amounts of Gag antigen due to high TCR avidity. PLoS Pathog. 6:e1000780. doi:10.1371/journal.ppat.1000780.
75. Vogelzang A, et al. 2008. A fundamental role for interleukin-21 in the generation of T follicular helper cells. Immunity. 29:127-137.
76. Wei L, Laurence A, Elias KM, O'Shea JJ. 2007. IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J. Biol. Chem. 282:34605-34610.
77. Williams LD, et al. 2011. Interleukin-21-producing HIV-1-specific CD8 T cells are preferentially seen in elite controllers. J. Virol. 85:2316-2324..
78. Yi JS, Cox MA, Zajac AJ. 2010. T-cell exhaustion: characteristics, causes and conversion. Immunology. 129:474-481.
79. Yi JS, Du M, Zajac AJ. 2009. A vital role for interleukin-21 in the control of a chronic viral infection. Science 324:1572-1576.
80. + T cells. J. Immunol. 178:788-797.
81. + T cells endowed with proliferative capacity. J. Exp. Med. 198:1909-1922.
82. Yu D, Vinuesa CG. 2010. The elusive identity of T follicular helper cells. Trends Immunol. 31:377-383.
83. + T cells are induced in acute and chronic progressive HIV infection and are associated with relative viral control. J. Immunol. 185:498-506.
84. + T cells are detectable in early human immunodeficiency virus type 1 infection. J. Virol. 82:6767-6771.
85. +T cell lineage differentiation. Immunity. 30:646-655